Neurocysticercosis (NC) or infection of the central nervous system with Taenia solium larvae is the leading cause of preventable epilepsy in endemic regions across the globe. Albendazole and praziquantel are commonly used antihelminthic agents to treat NC; however, viable cysts persist in the majority of patients, putting them at risk for future seizures and other neurological complications.
Generic Drug Names: albendazole, praziquantel Abstract: Neurocysticercosis (NC) or infection of the central nervous system with Taenia solium larvae is the leading cause of preventable epilepsy in endemic regions across the globe. Albendazole and praziquantel are commonly used antihelminthic agents to treat NC; however, viable cysts persist in the majority of patients, putting them at risk for future seizures and other neurological complications.
Because of their pharmacokinetic profiles, albendazole and praziquantel have the potential to interact with many different drugs. During antihelminthic treatment, antiepileptic drugs and corticosteroids are commonly co-administered to manage seizures and cerebral edema; however, the most commonly used agents from these drug classes are known to significantly alter plasma concentrations of albendazole and praziquantel.
The overarching issue with drug interactions during the treatment of NC is whether or not they have clinical relevance, as the plasma concentrations of albendazole and praziquantel have not been directly linked with eradication of viable cysts. Future studies should attempt to evaluate the validity of a causal relationship between antihelminthic plasma concentrations and outcomes so that drug interactions can be better understood and managed and so that treatment can be optimized. Abstract 48
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104
Antihelminthic treatment leads to degradation of encysted larvae by making the larvae 105 recognizable to the host's immune system. During treatment, the host immune response 106 against the cyst often leads to cerebral edema and consequently seizures. Corticosteroids 107 are routinely used to control edema and antiepileptic drugs (AEDs) are often used for 108 prevention of seizures, and both are commonly coadministered during antihelminthic 109 treatment of NC. 4, 7 The objective of this review is to evaluate the current evidence for 110 common drug interactions with albendazole and praziquantel during treatment of NC and 111 to identify gaps in the existing scientific literature. 112
113

Pharmacokinetics of Albendazole 114
Albendazole has low bioavailability after oral administration, which may be related to 115 poor absorption due to limited solubility. 
119
Albendazole is subject to high intrinsic clearance 12 which may be a result of poor 120 absorption, extensive first pass metabolism, or a combination of these factors. 121
Albendazole sulfoxide also exhibits a degree of plasma protein binding (62%-72%). 10 Albendazole sulfoxide is then converted into an inactive metabolite, 125 albendazole sulfone, a process that is also mediated by CYP450; however, the precise 126 isoforms responsible for this process remain unclear. 10, 14, 15 Because of the involvement of 127 CYP 3A isoenzymes in the formation of the active metabolite, it is not surprising that 128 inhibitors of CYP 3A, such as ritonavir, as well as inducers, such as phenytoin, may 129 influence plasma concentrations of albendazole sulfoxide.
16,17
131
The pharmacokinetics of albendazole are subject to high interpatient variability. The 132 population pharmacokinetics of albendazole were prospectively evaluated in a study by 133 Castro et al. in which 90 patients with NC received a standard regimen of 30 mg/kg/day 134 for 8 days.
18 In about one-quarter of patients, the bioavailability of albendazole was only 135 28%, compared with complete bioavailability modeled in roughly three-quarters of 136 patients. This substantial difference in bioavailability between this subpopulation and the 137 rest of the study participants was not accounted for by covariates such as age, sex, or 138 creatinine clearance, and concomitant drugs. Concurrent diet was not described in this 139 
Pharmacokinetics of Praziquantel 145
Praziquantel is a highly lipophilic molecule and is well-absorbed from the gastrointestinal 146 tract. 19 It is administered as a racemic mixture, with (-)-(R)-praziquantel being the 147 pharmacologically active enantiomer. 20 Praziquantel is metabolized by hepatic CYP 1A, 148 CYP 3A and CYP 2C isoenzymes into inactive hydroxylated compounds.
12 Similar to 149 albendazole, praziquantel is also subject to high intrinsic clearance, but in contrast, this is 150 probably due to its extensive first pass metabolism, rather than poor absorption. 151
Although its distribution has not been extensively studied, it has been reported that 152 praziquantel is 80% to 85% bound by plasma proteins. 13 The metabolism of praziquantel 153 makes certain drug-drug interactions easier to assess because unlike albendazole for 154 which CYP450 isoenzymes are involved in the formation of both the active and inactive 155 metabolite, with praziquantel, CYP450 isoenzymes are only involved in the conversion 156 of the active into the inactive metabolite. Drugs that inhibit CYP 3A isoenzymes, such as 157 ketoconazole, and drugs that induce CYP 3A, such as rifampin, may significantly 158 influence plasma concentrations of praziquantel. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 received albendazole (7.5 mg/kg every 12 hours) for 8 days and were divided by their 174 AED use for at least the last 3 months: no AED, phenytoin, carbamazepine, or 175 phenobarbital. In addition, 40% of patients received dexamethasone, during treatment 176 with albendazole for control of cerebral edema. Despite the high interindividual 177 variability of albendazole metabolite concentrations in the plasma, all 3 antiepileptic 178 drugs significantly reduced the mean maximum concentration (C max ) and area under the 179 concentration-time curve (AUC) of (+),-albendazole sulfoxide after 8 days of therapy 180 (Table 1) . Reduced bioavailability may have been explained by increased extraction 181 upon first pass metabolism secondary to the CYP inducing effects of AEDs on 182 albendazole. However, the role of plasma protein binding should also be considered 183 because phenytoin, carbamazepine, and phenobarbital have high plasma protein binding 184 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 25 In this 235 study, albendazole was given at a dose of 15 mg/kg divided into three daily doses for 8 236 days, followed by another 8 days when dexamethasone 8 mg was given with each dose of 237 albendazole. The mean plasma concentration of albendazole sulfoxide during the first 8 238 days without concurrent dexamethasone was 728 ng/mL (range 169 ng/mL to 2268 239 ng/mL), which increased by 56% to a mean of 1253 ng/mL (range 306 ng/mL to 1934 240 ng/mL) during the last 8 days when dexamethasone was given concurrently. Of the 8 241 patients in this study, all patients except one had increased albendazole sulfoxide plasma 242 concentrations when dexamethasone was added (range: -9% to 592%). 25 A larger sample 243 size may have helped determine if this increase in albendazole sulfoxide plasma 244 concentrations could be at least partially explained by interpatient variability. 245
246
Similarly, a study that compared an 8-day course of albendazole alone, albendazole with 247 dexamethasone, and albendazole with dexamethasone and cimetidine in patients with NC 248 found that dexamethasone significantly increased plasma concentrations of albendazole 249 sulfoxide. 26 The group receiving albendazole with dexamethasone had a median steady-250 state AUC of albendazole sulfoxide that was significantly higher compared with the 251 group that received albendazole monotherapy (4.7 mcg/h/mL vs. 2.3 mcg/h/mL; P<.05). 252
This study also evaluated oral clearance (CL/F) of albendazole sulfoxide, which was 253 The lower clearance observed with concurrent dexamethasone suggests that 256 dexamethasone increases plasma concentrations of albendazole sulfoxide by decreasing 257 its clearance, rather than affecting its formation. The pharmacokinetic profile of 258 albendazole sulfoxide was similar between the group receiving cimetidine with 259 albendazole and dexamethasone and the group receiving albendazole and dexamethasone 260 alone, suggesting that the increase in plasma concentrations was mainly due to the 261 addition of dexamethasone. As this was not a crossover study, it is also important to 262 consider the role of differences in drug disposition between patients as a potential source 263 of bias. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w
In our review of the literature, only drug-drug interaction studies with dexamethasone 276 were identified. In clinical practice, other agents such as prednisolone are also often 277 used. Because the mechanism of the drug interactions with dexamethasone is unclear, 278 the potential effect of other corticosteroids on the pharmacokinetics of albendazole and 279 praziquantel is unknown and should be studied. 280
281
Drug Interactions with Histamine-2 Antagonists and Proton Pump Inhibitors 282
Histamine-2 antagonists and proton pump inhibitors are often used to prevent the gastric 283 toxicity of corticosteroids in patients being treated for NC. As these agents can increase 284 gastric pH, their use can significantly alter the absorption of drugs that are absorbed only 285 at specific pH levels. In the literature, we only identified studies that evaluate drug-drug 286 interactions between albendazole and praziquantel with cimetidine. Additional studies 287 are needed that evaluate interactions with more commonly used histamine-2 antagonists 288 such as ranitidine, and proton pump inhibitors. 289
290
The absorption of albendazole may be pH dependent, as demonstrated by a drug 291 interaction study with cimetidine (a histamine-2 antagonist and CYP 3A inhibitor) and 292 grapefruit juice (a CYP 3A inhibitor). 33 In this study, administration of grapefruit juice 293 alone with albendazole increased albendazole sulfoxide C max and AUC significantly, 294 suggesting that albendazole is subject to mucosal CYP 3A isoenzyme metabolism. The 295 role of grapefruit juice in activating P-glycoprotein (P-gp) to modulate the bioavailability 296 of albendazole has also been considered; however, it does not appear that albendazole 297 interacts with P-gp. 34 In contrast, concurrent administration of grapefruit juice and 298 .022) and AUC 0-inf from 6.5 ± 5.1 mg/h/L to 3.5 ± 1.9 mg/h/L (P=.118) compared with 300 grapefruit juice alone. Although it may seem paradoxical that coadministration of two 301 CYP 3A isoenzyme inhibitors decreases plasma concentrations of a CYP 3A substrate, 302
this reduction in C max may actually be the result of inhibition of gastric acid secretion by 303 cimetidine, suggesting that absorption of albendazole is pH dependent. 33 However, in the 304 absence of a comparator group that only received cimetidine, this hypothesis is difficult 305 to support because cimetidine has not always shown a significant pharmacokinetic effect 306 when added to albendazole.
26
308
Unlike albendazole, it does not appear that the absorption of praziquantel is pH 309 dependent. In a crossover study evaluating the interaction between cimetidine and 310 praziquantel, coadministration of both agents after 3 doses increased mean C max from 1.8 311 ± 0.7 mcg/mL to 3.7 ± 1.5 mcg/mL, mean AUC from 6.6 ± 2.5 mcg/mL/h to 11.5 ± 4.6 312 mcg/mL/h and increased mean t 1/2 from 1.8 ± 0.5 hours to 2.4 ± 0.6 hours (P<.05 for all 313 comparisons).
35 T max did not significantly increase, suggesting that the addition of 314 cimetidine did not affect the absorption of praziquantel and that this drug-drug interaction 315 was mediated by CYP 3A inhibition. 
Drug Interactions with Food 318
Concurrent diet may be an important consideration during antihelminthic treatment 319 because food can have a significant effect on plasma concentration of both albendazole 320 and praziquantel. A two-way crossover study of 16 healthy volunteers evaluated the 321 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Compared with the fasting state, a high-fat meal increased albendazole sulfoxide C max 323 from 0.26 ± 0.1 mcg/mL to 1.8 ± 0.6 mcg/mL, AUC 0-inf from 5.1 ± 2.8 mcg/h/mL to 29.4 324 ± 14.6 mcg/h/mL, and T max from 3.2 ± 1.1 hours to 5.1 ± 1.6 hours (P<.05 for all 325 comparisons). In contrast, CL/F was reduced from 0.2 ± 0.2 mL/h (fasting) to 0.04 ± 326 0.02 mL/h (high fat meal), as well as volume of distribution (Vd/F), 3.0 ± 1.9 mL 327 (fasting) to 0.4 ± 0.2 mL (high fat meal) (P<.05 for both comparisons). Although a high 328 fat meal increased plasma concentrations of albendazole sulfoxide, there was significant 329 variability in pharmacokinetics among the participants of this study. This variability may 330 be influenced by additional factors, such as differences in gastric pH and drug 331 metabolism.
36
333
Similar to albendazole, concomitant administration of food with praziquantel has a 334 significant effect on its plasma concentrations. In a study by Castro et al., healthy 335 volunteers were randomly assigned to receive praziquantel 1800 mg with a high fat meal, 336 a high carbohydrate meal, or after 10 hours of fasting.
37 Mean C max was 318.8 ± 227.2 337 ng/mL among fasting participants compared with 1095.4 ± 780.0 ng/mL for participants 338 receiving the high fat meal and 1962.2 ± 779.8 ng/mL for participants receiving the high 339 carbohydrate meal (P<.05 for both comparisons). Mean AUC 0-8 was 882.3 ± 416.8 340 ng/h/mL among fasting participants compared with 2474.6 ± 1166.0 ng/h/mL for 341 participants receiving the high fat meal and 3276.2±969.7 ng/h/mL for participants 342 receiving the high carbohydrate meal (P<.05 for both comparisons). Since the high fat 343 meal also contained a high amount of carbohydrates, it is possible that it was the 344 The overarching issue with drug interactions during the treatment of NC is that the 369 clinical importance of albendazole and praziquantel plasma concentrations has not been 370 firmly established. A study that showed a single day of high dose praziquantel compared 371 with a standard weeklong regimen of albendazole was effective for treating NC provides 372 some anecdotal evidence that the cysticidal activity of praziquantel may be dose 373 dependent and therefore, plasma concentrations may be clinically important. 38 However, 374 a study of 29 patients did not find any correlation between plasma concentrations of 375 albendazole and praziquantel and cysticidal efficacy at 3 months. 39 What limits the 376 generalizability of this study is that the majority of the patients with an available 3 month 377 CT scan had complete disappearance of cysts, which is a finding that has not been 378 observed in large randomized controlled trials. 7, 8 Plasma concentrations of albendazole 379 and praziquantel should be taken and analyzed in future, large clinical trials to provide 380 stronger evidence to evaluate the validity of a causal relationship between antihelminthic 381 plasma concentrations and reduction in cysts. 382
383
Conclusions and Future Directions 384
Based on the available literature, there are significant route drug and food interactions 385 during treatment of NC with albendazole and praziquantel. Given the paucity of 386 outcome-based data, it is not possible to make evidence-based recommendations for 387 managing drug interactions with albendazole and praziquantel in patients with NC. 388
Studies are needed that provide evidence-based strategies for managing drug interactions 389 in NC (e.g., increasing or reducing the dose of antihelminthic agents). Furthermore, the 390 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
